Collegium Pharmaceutical, Inc. (COLL)

NMS – Real Time Price. Currency in USD

26.13

+0.15 (0.58%)

Market open: Aug 12, 2026, 1:09 PM EDT

26.38

+0.40 (1.56%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

06.08.2026

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

06.08.2026

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.

06.08.2026

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.

06.08.2026

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

01.08.2026

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Collegium Pharmaceutical, Inc. (COLL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Videos

No Data

Press releases

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Videos

No Data

Press releases

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Search stocks

Collegium Pharmaceutical, Inc. (COLL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Videos

No Data

Press releases

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Videos

No Data

Press releases

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress